Articles related to Allergy & Immunology

A phase 3, multicenter, double-blind, randomized, placebo-controlled trial was conducted to evaluate the efficacy and safety of epicutaneous immunotherapy with a peanut patch in children aged 1 to 3 years with peanut allergy. No approved treatment for peanut allergy exists for children under 4 years old. Participants with confirmed peanut allergy were assigned to either receive the peanut patch or a placebo daily for 12 months. The primary endpoint was the treatment response measured by the eliciting dose of peanut protein at 12 months. The trial showed that 67.0% of children in the intervention group demonstrated a treatment response compared to 33.5% in the placebo group. Adverse events occurred in both groups, with serious adverse events and anaphylaxis observed more frequently in the intervention group. However, serious treatment-related adverse events were rare. In conclusion, this trial demonstrated that epicutaneous immunotherapy with a peanut patch for 12 months was more effective than placebo in desensitizing children aged 1 to 3 years with peanut allergy and increasing their tolerance to peanut protein. Although adverse events were observed in both groups, serious treatment-related adverse events were uncommon. These findings suggest that epicutaneous immunotherapy may be a potential treatment option for young children with […]

The outbreak of blastomycosis was first noted in early March when several individuals from the plant were diagnosed with atypical pneumonias. The mill was idled for several weeks to be disinfected, but the source of the infection was never located.

Single-tablet regimen (STR) coverage under qualified health plans (QHPs) varies widely across the US. Although bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) coverage has grown over time, many QHPs in priority jurisdictions for the Ending the HIV Epidemic (EHE) have coinsurance requirements. Delay in QHP coverage and benefit design may hinder access to new antiretroviral treatment (ART) regimens.

Based on cases reported to the CDC, this study reports an acceleration in case detection, with a dramatic increase in 2021. From 2019 to 2021, 17 states identified their first case of C auris; however, resistance to echinocandins increased threefold in 2021 compared to the previous two years. And because screening is not conducted uniformly across the United States, the true burden of C auris cases is likely higher than reported.

“The point I want to make specifically to the young people in the crowd—the pre-docs, the postdocs, the young investigators—is that what happens in this meeting in a very incipient form over a period of time becomes the reality of what we are dealing with and then the implementation of something that’s clinically actionable,” Fauci said as the keynote speaker at the Conference on Retroviruses and Opportunistic Infections (CROI) 2023.

Reports on the Vaccine Safety Datalink flagged the need to investigate a potential increased risk those 65 years of age and older, for ischemic stroke in the first 21 days after receiving the bivalent Pfizer-BioNTech booster. FDA has parallel monitoring systems to confirm or fail to validate a safety signal. In this case, those other systems did not confirm the Vaccine Safety Datalink flag.